logo
Categories
Event

Access Miami 2024

ACCESS 2024

Let’s meet in Miami

Understand how you can transform market access performance and achieve excellence in market access and pricing with our latest digital innovations. 

Join us on Day 2, 11:45 to hear from our team on:

Transform Market Access Tracking with Access Hub™

The process of launching a new drug globally is complex and time-consuming, involving negotiations and approvals in multiple countries. To support this endeavour, an often small Global Market Access team collaborate with their country counterparts to facilitate the launch around the world. 

Many companies continue to face challenges due to reliance on tools like Excel, PowerPoint, and email as the primary collaboration channels. These outdated methods result in delayed and inconsistent access to data, limited collaboration, and ineffective tracking of key metrics.

To address these issues we launched Access Hub, an all-in-one digital market access dashboard and performance tracking tool, that’s been designed specifically for market access teams.

Through extensive user research, we have built an innovative online platform that centralises launch activity tracking, streamlines communication, fosters information sharing and captures essential KPIs.

Access Hub revolutionises global drug launches by empowering teams to make informed decisions, learn from past experiences, benchmark against competition, and showcase the success of their brands.

In this session our Head of Sales, Russ Leslie, will walk through Access Hub and how it’s supporting the most successful pharma companies to transform how they track market access performance.  

Get to know the Access Infinity team

Meet the team

Russ Leslie

Head of Sales

robert buckley

Senior Business Development Manager

Robert Buckley

Senior Business Development Manager

Thomas Gilboy

Product Owner

Margaret Labban

Product Manager

Join us on Day 2, __to hear from our team on:

Question statement

Our presentation on day 2 will focus on the needs of early market access teams, taking a deeper dive into how to produce more accurate analysis and evidence to support a product’s launch strategy, at pace.

In today’s pharma companies, the Market Access and Pricing function is providing a vital bridge between clinical and commercial functions. Analogues need to be considered at every stage, so that influencing drivers for price and market access can be evaluated.

In this session, our Founding Director Shri Rao Mukku will explore best practices in analysing analogues, as well as uncover the common mistakes we see in industry, offering our advice for how to avoid them.

Join the Access Infinity team at RAI Congress Centre Amsterdam 21st – 23rd March.

Best practices in estimating pipeline product prices for early market access teams

It goes without saying that analogues are a great choice for robust evidence because they tell us what’s historically happened to products in similar situations. Of course, there is no perfect analogue that 100% meets your own product, so how do you choose which ones to analyse and review?
There’s much to consider and a lot at stake, not to mention the time pressures you’re facing to answer complex questions, at pace.
So how can early market access professionals take a holistic approach to finding the right analogues in the right time frame?
Our Product Owner Thomas Gilboy explores this at EPA Congress, taking a deeper dive into:
· The analogue analysis challenges faced by today’s early market access teams[LB1]
· How to produce more accurate analysis and evidence to support a product’s launch strategy
· How to pick up the pace of analogue analysis [LB2] so that you can respond rapidly and accurately to enquiries from the [launch?] team

Let’s meet in person

The World EPA Congress 2022 is a great opportunity to share ideas. Block some time for a product demo or chat with our P&MA experts. We look forward to seeing you in Amsterdam.

Meet us at Booth 20.

About Access Infinity

Access Infinity is the world leader of digital transformation in the Pharma Industry. We are a trusted provider of digital platforms and consulting services to leading pharma companies

We come in two flavours

Consulting

The critical support you need to develop a successful value assessment and launch strategy.

Digital products

Time-saving digital solutions that help you launch your brand to the right patients, at the right price, at the right time.

We look forward to meeting you

ACCESS 2024 is a great opportunity to share ideas. Block some time for a product demo or chat with our P&MA experts. We look forward to seeing you in Miami.

Categories
Event

World EPA Congress 2024

World EPA Congress

Let’s meet at Booth 176

Join us at the the World EPA Congress where we’ll be sharing the latest insights from the Access Infinity team on industry hot topics.

Join us on Day 1, 2:05 pm for our panel discussion:

Metrics that Matter in Market Access Performance Tracking

Moderator:  Ahmed Edathodu, Founding Director, Access Infinity 

Panellists:  Chris Bidad, Global Head of Access Strategy & Payer Policy, AstraZeneca 

Adrian Harrington, Senior Director Value & Access, Biogen 

Robert Palmer, Head of Market Access, Oncology, Boehringer Ingelheim 

Market access is the bridge between clinical and commercial functions and plays a pivotal role in product launch. Success in market access is defined by the outcome of payer decisions – whether nationally or regionally. 

While measuring global market access performance has been on the agenda for some time, understanding success is becoming a priority at board and leadership level. 

How can market access leaders do it better, so they’re empowered to communicate their team’s success? 

In this this discussion, the panel explore the changing role of market access and the importance of tracking performance as a result. They take a deeper dive into how this can be done, the challenges it presents and how they can be overcome.  

Join the Access Infinity team at RAI Congress Centre Amsterdam 21st – 23rd March.

Join us on Day 2, 3:35 pm to hear from our Product Owner on: ​

Three ways AI will impact Market Access in 2024

In this session our Product Owner, Tom Gilboy will share three tangible use cases of AI for Market Access teams that could be ready to go this very year.  He will also share the capabilities Market Access teams need to build to avoid being left behind by the AI revolution. 

Join the Access Infinity team at RAI Congress Centre Amsterdam 21st – 23rd March.

Thomas Gilboy

Digital Solutions Product Owner Thomas Gilboy is the Product Owner at Access Infinity for our Market Access Digital Tools. As Product Owner, he leads the product development and leads the product development leads the product development and “blue sky thinking” of what is possible within the digital space for Market Access. Before Access Infinity, Tom worked for 10 years within Market Access in consulting and at ViiV. In consulting Tom delivered over 100 projects covering a broad range of Market Access topics from early pipeline decisions through to end of life cycle planning, across a broad range of therapy areas. At ViiV, Tom covered the successful European Market Access for one of their launching HIV brands.   

Get to know the Access Infinity team

Ahmed Edathodu

Founding Director

Keshav Nagaraja

Managing Director

Russ Leslie

Head of Sales

Isabel Rubio

Director

Louise Bennett

Head of Marketing

 

Robert Buckley

Senior Business Development Manager

THOMAS GILBOY​

Product Owner

Louise Bennett

Head of Marketing

 

Robert Buckley

Senior Business Development Manager

Thomas Gilboy

Product Owner

Margaret Labban

Product Manager

Best practices in estimating pipeline product prices for early market access teams

It goes without saying that analogues are a great choice for robust evidence because they tell us what’s historically happened to products in similar situations. Of course, there is no perfect analogue that 100% meets your own product, so how do you choose which ones to analyse and review?
There’s much to consider and a lot at stake, not to mention the time pressures you’re facing to answer complex questions, at pace.
So how can early market access professionals take a holistic approach to finding the right analogues in the right time frame?
Our Product Owner Thomas Gilboy explores this at EPA Congress, taking a deeper dive into:
· The analogue analysis challenges faced by today’s early market access teams[LB1]
· How to produce more accurate analysis and evidence to support a product’s launch strategy
· How to pick up the pace of analogue analysis [LB2] so that you can respond rapidly and accurately to enquiries from the [launch?] team

Let’s meet in person

The World EPA Congress 2022 is a great opportunity to share ideas. Block some time for a product demo or chat with our P&MA experts. We look forward to seeing you in Amsterdam.

Meet us at Booth 20.

About Access Infinity

Access Infinity is the world leader of digital transformation in the Pharma Industry. We are a trusted provider of digital platforms and consulting services to leading pharma companies

We come in two flavours

Consulting

The critical support you need to develop a successful value assessment and launch strategy.

Digital products

Time-saving digital solutions that help you launch your brand to the right patients, at the right price, at the right time.

We look forward to meeting you

The World EPA Congress 2024 is a great opportunity to share ideas. Block some time for a product demo or chat with our P&MA experts. We look forward to seeing you in Amsterdam.

Categories
Blog

Cutting through the noise: opportunities artificial intelligence presents to market access

The advent of ChatGPT is shining a spotlight on the possibilities of artificial intelligence (AI) across all industries. In the recent past, we witnessed machine learning algorithms primed with historical data turn it into generative outcomes – a method relied upon by ChatGPT as a large language model (LLM).

Beyond creative industries, we have also seen phenomenal innovation in the medical and health sectors due to AI. From fitness tracking apps to leveraging big data for diagnoses, AI is removing manual processes and delivering faster outcomes.

However, in terms of digital transformation, the pharma industry has lagged behind, particularly with regards to adopting new technologies at the same pace as other industries. Market access – being a relatively new and emerging function – has even more catching up to do. 

In the last decade, the role of market access has leapt forward significantly, and is now recognised as a core function within pharmaceutical organisations, playing a pivotal role in medicine launch and overall business success.

Meanwhile, internal digital teams have typically focused on using tech to advance departments such as R&D, medical affairs, commercial and marketing, leaving market access underserved.

The pharmaceutical industry is increasingly warming to the potential of artificial intelligence. Momentum on how AI could be used continues to build. Potential applications start from discovery and development through to clinical trials and, much like other industries, the possibilities are endless.

 

Extracting key insights from diverse datasets

With the accessibility of tools such as the above-mentioned ChatGPT, we have new avenues for intelligence within market access analysis and decision-making. For example, LLMs can be trained on vast data from market access databases, enabling teams to query them with relevant prompts to extract valuable insights.

Market access professionals often reflect on numerous and complex information from a wide range of data sources, including pricing data, payer research and HTA reports, all of which hold critical information that teams must painstakingly sift through manually. With so much data being captured from different sources, it becomes very difficult to find the most pertinent information that should be considered for evidence-based decision making. LLMs can excel at distilling extensive data sets into simple insights, saving hours of time and unlocking important evidence hiding in plain sight.

Not only can AI be trained to analyse and extract insights from unstructured and often subjective reports, often provided in various foreign languages; AI can also help automate health economic modelling, allowing for faster and more accurate assessments of a drug’s cost-effectiveness. It can also help in simulating different scenarios to assess the impact on market access.

Furthermore, AI can be used to predict launch success. This requires in-depth analysis of historical data, including commercial data, past pricing trends, timeframes for market entry, competitive dynamics, ROI projections and more. AI is ideally placed to analyse the data available, empowering market access specialists to better forecast and model success for their upcoming launches.  

Another consideration is the visualisation of data. As it stands today, custom visualisation of multiple data points is challenging and time-consuming for market access teams, but something that is in high demand by market access leaders and senior executives. The integration of AI into tools like Access Infinity’s NURO solution, streamlines the process, making the generation of charts and personalised visualisations effortless.    

The challenges of using AI in market access

While in theory, there are numerous opportunities to use AI within market access, it is still nascent in its technical journey. We need to overcome the barriers of poor digital maturity to truly leverage AI. It is certainly time for companies to stop relying on legacy methods – like Excel – to make decisions and start exploring the possibilities of more advanced and specialised tools.

Meanwhile, there are various limitations in the data itself, that limit the accuracy of the outputs and continue to create scepticism even among early adopters. Namely, we are still lacking sufficient data – we have around 2,500 brands that have been launched globally since 1995, and ideally, we would need a lot more data to train the models to improve the accuracy of predictions.

Standardisation efforts are ongoing but can be slow to adopt. The data is often stored in various formats and systems, making data analysis complex.

AI in practice

While there’s no doubt that AI can – and will – accelerate decision-making, it’s important not to lose sight of the bigger picture.

Market access is not just a science, wherein a given input, such as evidence, guarantees an output, such as price. It will continue to heavily rely on human intervention, judgement, and experience. Thus, the ‘art’ of Market Access is better served by combining human expertise and AI to ensure success.

We anticipate that AI will become one cog in the machine taking care of routine tasks, so that, there are more resources available to handle complex requirements that need human collaboration and intervention.  

Our best practice tips for beginning your journey towards using AI include the following:

  • Gather the largest sets of high-quality data, including relevant price, HTA, evidence and regulatory approvals to begin connecting the dots.
  • Experiment with multiple avenues and don’t shy away from exploration with a focus on refining prompt engineering and training datasets.
  • Partner with others to make major inroads without losing focus on your brands.

What exposure have you and your team had to AI? And what role do you see it playing for market access in the future?

Access Infinity has made exciting advancements in incorporating AI into our digital solutions. If you’d like to learn more, we’d love to hear from you. Get in touch at hello@accessinfinity.co.

Categories
News

Access Infinity recognised in 2023 GHP Magazine Healthcare & Pharmaceutical Awards

Most innovative digital pharmaceuticals platform 2023 UK

LONDON, UK — 3rd October, 2023, Access Infinity is delighted to be recognised in this year’s Healthcare & Pharmaceutical Awards, winning “Most innovative digital pharmaceuticals platform 2023 UK”.

This award marks the success of our Access Hub and Nuro platforms which are empowering Global Market Access leaders to work smarter, faster and more efficiently with valuable insights at their fingertips.

It’s also the second award win of the year for Access Infinity. Our Access Hub solution was recognised in this year’s Stevie® Awards, winning Technical Innovation of the Year.

In its eighth consecutive year, the Healthcare & Pharmaceutical Awards is here to remind us of how far we are truly progressing. Our quality of life is improving, we’re living longer, and we’re each experiencing a more progressive world when it comes to overall health. From a menopause training and education hub to pharmaceutical technology companies, healthcare SEO specialists to vitamin and supplements suppliers, and so much more, these awards celebrate the achievements of a superb selection of trailblazers in their respective sectors. 

GHP Magazine, endeavours to recognise those that are going above and beyond, or indeed, the businesses that are leading the industry forward, no matter how small their contributions might seem on the greater landscape. That’s why they launched their awards programme, and why they continue to spotlight the work of exceptional companies and individuals.

 

"It has been brilliant to host this year’s Healthcare & Pharmaceutical Awards programme. We’ve seen such a diverse mixture of businesses and individuals each creating a positive impact on their industries. They are consistently improving our world, while treating us all with compassion, care, and respect. Here’s to the future!”
Taylor Wilson
GHP’s Awards Coordinator

To find out more about the 2023 Healthcare & Pharmaceutical Awards, and see the full list of professionals selected in this year’s awards, please visit https://www.ghp-news.com/awards/healthcare-pharmaceuticals-awards

About Access Infinity

Founded in 2014, Access Infinity exists to help pharma companies confront their challenges head-on. The company began as a consulting firm to guide pharma businesses in developing and implementing effective market access and pricing strategies. It has since introduced market-redefining digital tools, NURO, Access Hub and Evidence Library to help market access teams work smarter, faster, and more efficiently with valuable insights at their fingertips.

With offices in London, Hyderabad, New York, and Manchester, Access Infinity is experiencing rapid growth as it continues to transform and simplify market access for pharmaceutical organizations globally. Clients include GSK, BMS, Astra Zeneca, Johnson & Johnson, Pfizer, and Amgen.

About GHP Magazine

Global Health & Pharma Magazine (GHP) was initially launched to act as an information sharing platform for those in the healthcare and pharmaceutical industries. Though it maintains this founding cornerstone, the magazine itself, with a circulation of 110,000 globally, has expanded in scope to magnify the work of those that are setting the pace and looking to change their respective sectors for the better.

 
For more information, press only:
Tel: +44 (0)20 4583 5450
Categories
Join us

Technical PM/Scrum Master

Are you a highly skilled and dynamic Technical Project Manager/Scrum Master with a passion for driving innovation and excellence in the world of SaaS technology? Do you thrive in fast-paced environments and possess a proven track record of successfully leading and delivering complex technical projects? If you’re ready to take your career to the next level and join a cutting-edge SaaS team that’s at the forefront of innovation, we want to hear from you. Access Infinity Digital is an innovative SaaS company and is seeking a Technical Project Manager to spearhead our technical initiatives, collaborate with a talented team of professionals, and shape the future of our industry-leading products. If you’re ready to embrace the challenge and help us build the future, read on to learn more about this exciting opportunity.

 

What we can offer:

A leadership team with more than half a century of the highest-level pricing and Market Access and digital solutions development experience means that Access Infinity is a great place to develop your skills in the field as part of our innovative and growing team.

  • You will learn the best practices in product development and project management from leaders in the industry, in a friendly and fun environment
  • Support will always be available from the senior team in an accessible, flat company structure
  • Development opportunities and performance/promotion reviews to accelerate your development
  • We believe in rewarding high performance and offer a generous compensation package

Job overview:

As a Technical Project Manager at Access Infinity, you will play a pivotal role in leading and managing the successful delivery of complex technical projects that drive our innovative SaaS offerings. You will collaborate closely with cross-functional teams, including software developers, engineers, quality assurance experts, and product managers, to ensure the timely and high-quality execution of projects. Your ability to balance technical expertise with effective project management skills will be essential in our mission to continually push the envelope of innovation.

What we are looking for:

Key Responsibilities 

1. Project Planning and Strategy:

  • Work closely with stakeholders to define project scope, objectives, and deliverables.
  • Develop comprehensive project plans, timelines, and resource allocation strategies.
  • Experienced with executing projects using Agile/Scrum methodology
  • Experience of Set-up, planning and scheduling projects within Jira or Azure DevOps

2. Technical Leadership

  • Possess a strong understanding of Web/UI, API and DB technologies
  • Provide technical guidance and expertise to project teams, ensuring that solutions align with best practices and industry standards.
  • Collaborate with engineering and data teams to resolve technical challenges and ensure project success.

3. Project Execution 

  • Oversee project execution, monitoring progress against milestones, and ensuring adherence to project timelines and budgets.
  • Identify and mitigate project risks and issues promptly.
  • Deliver Status Reports, Project health (time and money) reports and end of project wrap up reports

4. Team Collaboration:

  • Foster a collaborative work environment, ensuring effective communication and knowledge sharing among team members.
  • Lead cross-functional project teams, including Data, Product Management, UX and Engineering, providing direction and support to achieve project goals.

5. Quality Assurance

  • Implement quality control processes to ensure the delivery of high-quality software solutions.
  • Conduct thorough testing and validation of project deliverables.

6. Stakeholder Communication:

  • Maintain clear and open lines of communication with project stakeholders, providing regular updates on project status, risks, and changes.

7. Documentation:

  • Create and maintain project documentation, including technical specifications, requirements, and project reports. 

8. Continuous Improvement:

  • Champion a culture of continuous improvement, seeking opportunities to enhance project management processes and methodologies.

Qualifications:

  • Overall 6-10 years of experience with Project Management experience of 3-5 years
  • Project Management experience on .Net platform or Java platform – hands-on experience must
  • Fair knowledge of MS SQL Server or other RDBMS platform – hands-on experience must
  • Good working knowledge of Agile/Scrum and Iterative methodologies
  • Excellent Oral and Written English communication skills
  • PMP, Prince II (or equivalent) or CSM qualification is desirable
  • Quality assurance testing understanding / experience is an advantage
  • Experience working on creation / maintenance of a software product is an advantage
  • Experience of creating functional and technical specifications with the UX and development teams
  • Must be a team player willing to get hands dirty

Benefits

  • Indicative salary range – INR 25-30 Lakhs.
  • Comprehensive health insurance benefits.
  • Opportunities for professional growth and development.
  • Collaborative and innovative work environment.

Please email your CV and cover letter along to careers.india@accessinfinity.com with the role you are applying for as the subject.

Categories
Blog

Build or buy? Considerations for market access

As healthcare systems and regulatory landscapes evolve, pharmaceutical companies are facing greater challenges in getting their products to market. Market access professionals continue to play a critical role in navigating these complexities by ensuring timely regulatory approvals, cost-effectiveness evaluations, and securing favourable reimbursement and access agreements with healthcare providers and payers. As such, an increasing number of market access professionals are looking for digital solutions that bring efficiencies and allow them to make data-driven decisions.

However, as the demand for innovative digital strategies rises, a pivotal decision awaits these companies: Should they build an in-house digital application or buy pre-existing solutions from external vendors?

In this article, we delve into the complexities of this decision-making process and explore the key considerations that will empower market access teams to navigate the route towards the most optimal and cutting-edge digital solutions.  Read on to discover the pros and cons of both options and why we believe buying reigns supreme, nearly every time.

When should you BUILD?

Developing custom internal systems can prove advantageous when you want to retain full control over your unique processes and workflows. It is especially advantageous for systems that give a competitive edge or involve sensitive intellectual property. Bespoke home-grown solutions are also a better choice if off-the-shelf solutions seem too generic in comparison, and do not meet your specific needs.

Key considerations for BUILD

Building bespoke internal applications is not straightforward and can be complicated even for well-resourced teams.

1. Are you clear on your requirements?

When it comes to creating a custom application, having well-defined and documented requirements is crucial. Often, IT teams lack expertise in the subject matter and rely on their colleagues from the business side to explain what’s necessary. This means that if the main users (for market access, which includes both global and country teams) don’t actively contribute to shaping the requirements, the final solution may not be optimal. This challenge can be even greater for pharmaceutical companies due to their intricate organisational structure, the involvement of affiliates, and complex reporting hierarchies.

2. Are all your key stakeholders and users ready to commit time?

Consequently, the primary responsibility lies with the core market access team leading the custom application development. They must invest time in defining the requirements, providing clarifications to the IT team during the development phase, and conducting thorough end-user testing before release. Given the typically demanding schedules of market access professionals, this becomes a crucial factor to consider.

3. Have you considered the total cost of ownership?

Building software in-house carries higher development costs, longer timeframes and a risk of errors and defects — which can delay the roll-out. It is never a one-time effort and a one-off cost. There will be a need to commit to an ongoing budget and resources to provide support and take care of enhancements.

4. Have you considered the time it will take before you can start using the application?

Any bespoke application development follows a certain cadence.

It has to start with a detailed requirements elaboration phase so that the high-level requirements are well understood and documented. Starting with designing the user experience which requires intense end-user workshops, development of the application and testing, coupled with tight project management means that the entire process may take 6-12 months to complete. Many times, key personnel involved in the project change, the requirements evolve, and the end application doesn’t get the uptake that was expected.

Plug and Play: Explore the Perks of Purchasing SaaS

Although building software in-house can be a fantastic solution when done correctly — the reality is that for most companies, it’s simply not a practical option as they don’t have the necessary time or resources.

Market access teams in many pharma companies are accelerating their digital transformation by purchasing third-party software, that is then integrated into their existing operations and processes. This is particularly true when purchasing solutions from companies that specialise in market access and have built tailor-made solutions that cater to their needs.

Some unique advantages that SaaS solutions offer include:

  1. Lower total cost of ownership: Purchasing a SaaS solution does not have an upfront cost, and it is much easier to end the contract if businesses decide they no longer need the application. They can also benefit from new features and upgrades, without having to pay for all of them.
  2. Faster roll-out:  You start getting the value from day 1, as there is minimal set-up time involved in a SaaS solution.
  3. Customisation opportunities: Good SaaS platforms allow for many customisation opportunities to tailor to specific internal taxonomy and processes.
  4. Integrate to avoid duplication: Many SaaS platforms allow for integration with other internal and third-party applications. This eliminates duplication of efforts and increases adoption.
  5. Drive standardisation: Rolling out a SaaS solution already used by other leading pharma companies helps businesses stand a better chance of getting buy-in from the users. With an out-of-the-box system, pharmaceutical organisations are able to push through process standardisation and benchmark against some of the best in the industry.
  6. Try before you buy: Questions can be easily answered by gaining trial access, and simultaneously allay any concerns that the users may have.
  7. Long-term value and rate of adoption: Unlike a home-grown system that has been used by a handful of people, a SaaS solution benefits from years of evolution and feedback from clients — so a new client coming on board automatically benefits from having a robust, time-tested solution that already has the seal of approval by other businesses in the industry.

Building bespoke own solutions comes with risks, and adding to the complexity is the dearth of purpose-built SaaS solutions that cater to the digitisation needs of market access. So, it’s better for companies to avoid adopting generic or suboptimal applications. We have seen several market access teams try to build their own solutions and fail. This is particularly true for global launch activity tracking solutions that rely on affiliate teams to input lots of data into a system that isn’t easy to use. As a result, hardly anyone uses these applications, and it costs businesses a lot of money.

Discover our solutions

At Access Infinity, we have years of experience building solutions for market access and pride ourselves on delivering purpose-built platforms for Business Development, Pipeline, Early Assets and Launch teams.

Want to know more? Get in touch with our team, or browse our solutions, here.

Categories
Event

ISPOR Europe 2023

Let’s meet in person

ISPOR Europe is a great opportunity to share ideas. Block some time for a product demo or chat with our P&MA experts. We look forward to seeing you in Copenhagen. 

Meet us at Booth C3-087.

About Access Infinity

Access Infinity is the world leader of digital transformation in the Pharma Industry. We are a trusted provider of digital platforms and consulting services to leading pharma companies

Our products and services

Consulting

The critical support you need to develop a successful value assessment and launch strategy.

Digital products

Our cloud-based apps for rapid business intelligence, KPI tracking, access and evidence planning.

We look forward to meeting you

ISPOR Europe is a great opportunity to share ideas. Block some time for a product demo or chat with our P&MA experts. We look forward to seeing you in Budapest. 

Categories
Blog

What is Analogue Analysis?

It’s no secret that the landscape for market access and pricing professionals is ever-changing. Today the role of the function has evolved to be a critical link between R&D, medical and commercial functions. It’s providing the foundation for clarity in evidence expectations, willingness to pay and market needs, all while communicating and connecting pharma’s other functions.

Within this challenging environment, data-driven decision making is fundamental to overall business success. Enter, analogue analysis – the process of looking at past products’ performance to guide strategy and planning for current and future brands

An “analogue” is essentially a brand in a similar situation to your own. No brand is entirely the same as another, but it can have many of the same characteristics. Analysing these analogue brands can provide critical insight for our own brands, as they have already navigated through similar waters.

Why is analogue analysis beneficial?

When we predict the price and health technology assessment (HTA) outcomes of pharmaceutical brands, we base many of our assumptions on previously approved drugs – otherwise known as analogues. This competitor analysis in the pharmaceutical industry is essential for benchmarking price and informing product launch strategies.

In market access, we have time pressures to answer a range of complex questions. We need to know how to produce more accurate analyses and provide evidence to support a product launch strategy. From TPP profile definition through to price estimation, we need to speed up analysis to present the best business cases for early asset investment decision committees.

Important considerations for analogue analysis

When searching for analogues, we might look at defining characteristics such as:

  • Product and disease characteristics
  • Considerations for the launch environment
  • Broad or specific product launches.

We also need to ask ourselves some key questions. For example, what pricing opportunities are there in a highly genericised landscape? Does our product have an orphan indication? What does differentiation look like in a crowded marketplace? How can we support a trial design acceptable to payers if our comparator is off label?

TPP versus aspiration-led approaches

Analogues are selected using one of two approaches. One involves starting with what you have and using your existing TPP to identify analogues.  Another is more aspirational, defining outcomes you wish to achieve and identifying analogues that achieved those outcomes.

The TPP-led approach

In this approach, analogues are selected based on how well they match to the target product profile (TPP) for the brand. 

This approach works well when the TPP is available, however, it can be long and iterative, as many different TPP variations are introduced.  It is also difficult for market access teams to influence clinical programmes and medical strategies to shape the TPPs. 

Aspirational pricing and market access approach

This approach is based on a target price, and HTA outcomes that are expected to achieve the price. We need evidence to reach the desired HTA outcomes, which we can achieve by reverse engineering the TPP.

This makes it possible to guide research and development teams on trial designs and optimal products, but it may be far from reality. Whatever the findings, adequate risk analysis in the pharmaceutical industry is paramount, so whatever is identified must be robust.

Best practices for analogue analysis

Many teams face challenges, whichever approach is followed.  Analogue identification is frequently restricted by limitations on yours and your team’s knowledge.  Up to eight in ten analogues are selected based on team members’ personal knowledge, rather than being identified in a systematic manner.

At Access Infinity, we have developed Nuro to help you identify analogues, and get the best out of your analogue assessments. We generally advise this approach to get the best results:

Step 1: Define product or disease characteristics

This may include therapy areas, clinical benefits, molecule types, acute or chronic treatments, orphan drug indication, route of administration, and adult or child use.

Step 2: Define the launch environment

This may include size of target population, number of indicated products, availability of price benchmarks, competitor activity and off-label/on-label comparators.

Step 3: Apply criteria comprehensively and systematically

Bearing in mind that the above factors are not exhaustive, we need to take a comprehensive approach. This means starting with all EMA or FDA approved products. We need to be systematic when applying matchability of criteria. This will ensure repeatability, making for better business cases.

Step 4: Create the funnel

With these steps, we can then create our own funnels, for example, filtering out other therapy areas and focusing on auto-immune disorders. But we also need to be aware of the limitations, and draw on our own experience in addition to existing data. Generally, nine in ten analogues start with the disease, but we cannot simply create a funnel in any order.

The future

As pharmaceuticals become more expensive and competitive, we need faster, more reliable methods to benchmark pricing and assist product launches. Technology such as Nuro helps us to see all the essential data in one dashboard, which we can augment with our own experience.

No single method is the ‘correct’ one for getting a product to market effectively, as there are so many variables. What we can do is refine our strategies by looking at historical data and grouping by key characteristics. In future, this will help us satisfy HTA outcomes faster and create competitive price benchmarks.

Find out more about Nuro for analogue analysis here.

You can also hear our Founding Director Shri Rao Mukku talk more about analogue analysis in this webinar recording: https://accessinfinity.com/webinar/analogue-analysis-dos-and-donts/

Categories
Blog

5 reasons to track market access performance

As the role of the market access function continues to evolve, tracking its performance is becoming more important. Today, market access is the bridge between clinical and commercial functions and plays a pivotal role in launch (and overall business) success.

With market access performance becoming increasingly on the agenda at board and leadership level, understanding why it matters becomes paramount. That’s why we are rounding up our top 5 reasons to track market access performance to help market access teams work smarter, faster, and more efficiently.

1. Understand if we are making improvements:

One of the primary benefits of tracking market access performance is the ability to gauge whether improvements are being made. By using benchmarks such as competitor data or our own historical data, companies can set targets or adjust them in line with changing market conditions and evaluate their progress over time. This enables them to identify areas of success and areas that require further attention. Regular assessment of market access performance ensures that strategies are continuously refined and optimised to achieve better outcomes.

2. Quantify market access success:

Tracking market access performance allows professionals to quantify the value they bring to the business from a price and access perspective. Measurable figures allow market access professionals the chance to showcase their value to wider commercial teams. These figures help tell the story of the business, showcasing the impact of pricing and access strategies on the company’s overall success. This quantitative evidence strengthens their position and highlights the value they bring to the organisation.

3. Make better predictions:

Market dynamics are constantly evolving, making it crucial for businesses to anticipate and plan for the future. By tracking market access performance, companies can build on information from the public domain and their previous pricing or access strategies. This enables them to make more accurate predictions and informed decisions regarding future product launches. Looking both backward and forward allows organisations to learn from past experiences and adapt their strategies to align with changing market conditions.

4. Build institutional knowledge:

Tracking market access performance generates a wealth of data that can be consolidated into an accessible dashboard. This centralised platform ensures that all stakeholders can stay informed and build their institutional knowledge. By leveraging this knowledge, businesses can make informed decisions and seize opportunities while mitigating potential pitfalls.

5. Navigate changing market conditions:

With the volatility of drug pricing, understanding value-based pricing is critical. By continuously tracking market access performance, companies can identify trends and patterns over time. This insight allows them to adapt pricing and access strategies to align with evolving market dynamics. By staying ahead of the curve, businesses can navigate changing market conditions effectively and maintain a competitive edge.

Key takeaways

As we look ahead to the future, it is evident that the trends shaping market access performance will continue to gain momentum, especially with the rapid advancements in technology. By monitoring and evaluating market dynamics, companies can identify areas for improvement, quantify their value, make accurate predictions for the future, build institutional knowledge, and navigate changing market conditions. Through the continuous refinement of market access strategies, businesses can enhance their product launch strategies and ultimately benefit patients, who can get faster access to lifesaving healthcare.

The 5 reasons to track market access performance are also available as an infographic, download below. 

If you want to find out more about market access performance tracking then you can request access to our ultimate guide to tracking performance in market access by filling in the form below.
Categories
Join us

QA/Test Engineer

What we can offer:

A leadership team with more than half a century of the highest-level pricing and Market Access experience means that Access Infinity is a great place to develop your skills in the field as part of our innovative and growing team.

  • We have a strong training and development programme with 20+ learning modules to give you the best start to your global market access career. These include subject matter training in market access and pricing as well as transferable skills such as project management and presentation writing
  • You will learn the best practices in project management from true leaders in the industry, in a friendly and fun environment
  • Support will always be available from the senior team in an accessible, flat company structure
  • Development opportunities and performance/promotion reviews to accelerate your development
  • We believe in rewarding high performance and offer a generous compensation package

About you:

We seek experienced QA/Test Engineers to join our fast-growing Digital Solutions team to work on new feature development, enhancements and bug-fixes for our suite of digital products that support Market Access teams for our Pharma customers. We are looking for people who have a proactive, solution-oriented approach, are great at managing their time and strong communicators.

What we are looking for:

Key Responsibilities 

  • Review requirements and provide timely and meaningful feedback
  • Create detailed, comprehensive and well-structured test plans and test cases
  • Estimate, prioritize, plan and coordinate testing activities
  • Design, develop and execute automation scripts using open source tools
  • Identify, record, document thoroughly and track bugs
  • Perform thorough regression testing when bugs are resolved
  • Develop and apply testing processes for new and existing products to meet client needs
  • Liaise with internal teams (developers and product managers) to identify system requirements
  • Track quality assurance metrics, like defect densities and open defect counts
  • Perform RCA for defects and identify patterns and opportunities to improve software quality
  • Stay up to date with new testing tools and test strategies

Technical Skillset:

  • Strong knowledge of software QA methodologies, tools and processes
  • Hands-on experience with Functional Testing, NFR Testing and UI Testing
  • Knowledge of databases and SQL queries
  • Hands-on experience with automated testing tools like Selenium, JMeter
  • Hand-on experience with Defect management tools like Azure DevOps / Jira
  • Experience with performance and/or security testing is a plus

Qualifications:

  • 2-5 years’ experience as a QA Engineer
  • Experience of working in Agile, Iterative and Waterfall projects
  • Strong communication and inter-personal skills.
  • Strong documentation skills required

Please email your CV and cover letter along to careers.india@accessinfinity.com with the role you are applying for as the subject.